Skip to Content

New Drug Approvals Archive - February 2012

February 2012

Sklice (ivermectin) Lotion

Date of Approval: February 7, 2012
Company: Sanofi Pasteur Inc.
Treatment for: Lice

Sklice (ivermectin) Lotion is a pediculicide indicated for the topical treatment of head lice infestations in patients 6 months of age and older.

Read more: Sklice (ivermectin) FDA Approval History

Mitosol (mitomycin) Ophthalmic Solution

Date of Approval: February 7, 2012
Company: Mobius Therapeutics, LLC
Treatment for: Glaucoma Surgery

Mitosol (mitomycin) is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery.

Read more: Mitosol (mitomycin) FDA Approval History

Zioptan (tafluprost) Ophthalmic Solution - formerly Saflutan

Date of Approval: February 10, 2012
Company: Merck & Co., Inc.
Treatment for: Glaucoma (Open Angle), Intraocular Hypertension

Zioptan (tafluprost ophthalmic solution) is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Read more: Zioptan (tafluprost) FDA Approval History

Testosterone Gel (testosterone) Topical Gel - formerly Bio-T-Gel

Date of Approval: February 14, 2012
Company: ANI Pharmaceuticals, Inc.
Treatment for: Hypogonadism -- Male

Testosterone gel is a once-daily transdermal testosterone gel for the treatment of male hypogonadism or low testosterone levels.

Read more: Testosterone Gel (testosterone) FDA Approval History

Korlym (mifepristone) Tablets

Date of Approval: February 17, 2012
Company: Corcept Therapeutics
Treatment for: Cushing's Syndrome

Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance.

Read more: Korlym (mifepristone) FDA Approval History

New Drug Approvals Archive